Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer
- PMID: 2648838
- DOI: 10.1016/s0002-9378(89)80054-7
Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer
Abstract
Serum CA 125 levels and surgical findings were prospectively compared in 96 secondary laparotomies performed on patients with epithelial ovarian cancer. All patients had documentation of an elevated CA 125 level (greater than 35 U/ml) at a time when ovarian cancer was present, and thus the tumors were known to be "marker positive." Operation was performed in 45 patients who were clinically free of disease and in 51 patients in whom there was clinical evidence of disease. At the time of operation, 29 patients had normal CA 125 levels; persistent disease was documented in 18 (62%) of these. Of the patients with normal CA 125 levels at the time of operation, those with persistent disease had a significantly higher mean CA 125 level (16.9) than those with no disease detected (8.8, p = 0.001). At exploration, cancer was found in 84 patients. There was a correlation between the maximum diameter of the largest residual tumor mass and the accuracy of the CA 125 level as follows: microscopic to 1 cm disease, 55% accuracy; greater than 1 to 5 cm disease, 80% accuracy; greater than 5 cm disease, 92% accuracy (p = 0.013). There was no correlation of CA 125 accuracy with the patient's age, number of months from initial diagnosis, tumor stage, grade, or cell type, or the highest-ever level of CA 125. Of the 84 patients with tumor found at exploration, 66 had elevated CA 125 levels, yielding a sensitivity of 78.5%. There were 12 patients with no tumor found at exploration; 11 of these had normal CA 125 levels. The one patient who had an elevated CA 125 level subsequently had a recurrence; the corrected specificity is thus 100%. An elevated CA 125 level is an accurate predictor of persistent disease. Most of these patients will have gross tumor present. The accuracy of the CA 125 level in detecting disease is related to the amount of tumor present. In our population, the predictive value of an elevated CA 125 level was 100%; the predictive value of a normal CA 125 level was 38%.
Similar articles
-
Value of serum 125Ca levels: does the result preclude second look?Gynecol Oncol. 1989 May;33(2):201-3. doi: 10.1016/0090-8258(89)90552-0. Gynecol Oncol. 1989. PMID: 2703182
-
OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.J Clin Oncol. 1993 Aug;11(8):1506-10. doi: 10.1200/JCO.1993.11.8.1506. J Clin Oncol. 1993. PMID: 8336189
-
Use of CA 125 to monitor patients with ovarian epithelial carcinomas.Gynecol Oncol. 1989 May;33(2):193-7. doi: 10.1016/0090-8258(89)90550-7. Gynecol Oncol. 1989. PMID: 2703180
-
[Ovarian carcinoma antigen (CA 125) and ovarian cancer (clinical follow-up and prognostic studies)].Orv Hetil. 1993 Apr 25;134(17):915-8. Orv Hetil. 1993. PMID: 8479736 Review. Hungarian.
-
What do CA 125 and other antigens tell us about ovarian cancer biology?Acta Obstet Gynecol Scand Suppl. 1992;155:85-93. doi: 10.1111/j.1600-0412.1992.tb00012.x. Acta Obstet Gynecol Scand Suppl. 1992. PMID: 1502896 Review.
Cited by
-
A novel human monoclonal antibody against cervical cancer: its immunoreactivity with normal tube and ovary and with ovarian tumor tissue.Arch Gynecol Obstet. 1995;256(4):177-84. doi: 10.1007/BF00634489. Arch Gynecol Obstet. 1995. PMID: 7503589
-
Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer.Sci Rep. 2021 Sep 14;11(1):18190. doi: 10.1038/s41598-021-97564-1. Sci Rep. 2021. PMID: 34521891 Free PMC article.
-
The role of chemotherapy including ifosfamide for ovarian carcinoma. Austrian Collab. Ovarian Cancer Study Group.Cancer Chemother Pharmacol. 1990;26 Suppl:S30-2. doi: 10.1007/BF00685413. Cancer Chemother Pharmacol. 1990. PMID: 2347046 Clinical Trial.
-
TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients.BMC Cancer. 2010 Apr 13;10:139. doi: 10.1186/1471-2407-10-139. BMC Cancer. 2010. PMID: 20388222 Free PMC article.
-
Limitations to the use of the CA-125 antigen level in ovarian cancer.Curr Oncol Rep. 2003 Jul;5(4):263-4. doi: 10.1007/s11912-003-0063-1. Curr Oncol Rep. 2003. PMID: 12781066 Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials